Abstract
Objective
To develop the missing link between hyperuricemia and hypertension.
Methods
The study was conducted in Department of Biochemistry in collaboration with Nephrology Unit of Internal Medicine Department. Hypertension was defined according to blood pressure readings by definitions of the Seventh Report of the Joint National Committee. Totally 205 newly diagnosed and untreated essential hypertensive cases and age-sex matched normotensive controls were enrolled in the study. The potential confounding factors of hyperuricemia and hypertension in both cases and controls were controlled. Uric acid levels in all participants were analyzed.
Results
Renal function between newly diagnosed hypertensive cases and normotensive healthy controls were adjusted. The mean serum uric acid observed in newly diagnosed hypertensive cases and in normotensive healthy controls were (290.05±87.05) µmol/L and (245.24±99.38) µmol/L respectively. A total of 59 (28.8%) participants of cases and 28 (13.7%) participants of controls had hyperuricemia (odds ratio 2.555 (95% CI: 1.549-4.213), P<0.001).
Conclusions
The mean serum uric acid levels and number of hyperuricemic subjects were found to be significantly higher in cases when compared to controls.
Keywords: Newly diagnosed hypertension, Serum uric acid, Hyperuricemia, Joint National Committee
1. Introduction
Hypertension is the emerging public health problem of adult population across the globe, affecting one in every four individuals[1]. The etiological factors associated with hypertension is difficult to predict because hypertension results from a complex interaction of genes and environmental factors[1]. Different studies advocate the association between serum uric acid level and hypertension. The reasonable mechanism for the development of hypertension in hyperuricemia includes: (a) uric acid induced activation of renin-angiotensin system and action on glomerular apparatus[2],[3]; (b) increased insulin resistance and hyperinsulinaemia, causing decreases excretion of uric acid, sodium, potassium from renal tubules[4],[5]; and (c) uric acid action in proliferation of vascular smooth muscle[6], endothelial dysfunction with decrease nitric acid production [7],[8]. However, there are numerous confounding factors including metabolic syndrome, diabetes mellitus, chronic kidney disease, obesity, alcohol consumption, salt intake, fluid volume status ect. in the association of hyperuricemia and hypertension. Thus our main objective was to find out the association between hyperuricemia and hypertension by controlling aforementioned potential confounding factors.
2. Materials and methods
2.1. Study design and the participants
This hospital based cross-sectional study was conducted in the Department of Clinical Biochemistry in collaboration with Department of Internal Medicine (Nephrology Unit), Tribhuvan University Teaching Hospital, Institute of Medicine (Tribhuvan University Teaching Hospital, Institute of Medicine). Tribhuvan University Teaching Hospital is a tertiary care hospital in capital city of Nepal and it provides the health services to patients who visit to Tribhuvan University Teaching Hospital from different part of Nepal. Hence this site was chosen for the study.
2.2. Data collection
This study was carried out from 2009 February to 2011 August. The study population included patients visiting medical out patients door (OPD) and nephrology unit of Tribhuvan University Teaching Hospital from different parts of Nepal. A medical history was taken and a physical examination was performed by a physician. Only newly diagnosed hypertensive cases were included in the study. Hypertension was defined by blood pressure ≥140/90 mm Hg[9]. Subjects were resting for at least 20 min before taking the blood pressure. Blood pressure measurement was done using aneroid sphygmomanometer with an adequate cuff size. Systolic blood pressure (SBP) was taken by the first heard sound (Korotkoff Phase I). Diastolic blood pressure (DBP) was recorded at the level when the sound just disappeared (Korotkoff Phase V) or sometimes the K4 point, where the sound is abruptly muffled[10]. Weight was taken using a platform weighing machine. Standing height measurement was done with the participants in bare foot, eyes looking ahead. After having the written consent from the participants, 205 newly diagnosed hypertensive cases, ranging from 16 years to 65 years were eligible for the assessment of biochemical profile. We measured biochemical profile including uric acid, creatinine, total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and triglyceride (TG). Furthermore, age-sex matched normotensive healthy controls were also enrolled and all biochemical profile was done similar to cases. Demographic data including age, sex, weight, height, body mass index (BMI), physical activity, smoking status, alcoholic status and family history of hypertension were collected from the participants. Participants with haemophilia and recent cancer chemotherapy were excluded from the venipuncture. Five millilitres of blood was drawn after an overnight fast (12 h) by venous puncture and a routine urine sample were also collected. After clotting of blood, serum was separated within an hou by centrifugation at 5 000 g for 5 min. Serum was used for analysis of biochemical profile. Laboratory standard operation procedures were maintained for all laboratory analysis. Internal quality control sera, both normal and pathological, were also run for each lot of the test, for the validation of the results.
2.2.1. Inclusion criteria
Age between 16 years to 65 years with newly diagnosed hypertension and normotensive healthy controls were enrolled as a study group.
2.2.2. Exclusion criteria
For study cases: Age <16 years and >65 years, gout, chronic alcoholics, leukemias, polycythemia, lymphoma, carcinoma, anti-cancer therapy, psoriasis, pregnancy, diabetes mellitus, chronic diseases causes tissue break down, tuberculosis, chronic obstructive pulmonary disease, chronic renal failure, end stage renal disease, endocrine disorder, patients under medication for diabetes mellitus, hypertension were excluded from the study.
For healthy controls: Age <16 years and >65 years, gout, chronic alcoholics, leukemia, polycythemia, lymphoma, carcinoma, anti-cancer therapy, psoriasis, pregnancy, chronic disease causes tissue break down, tuberculosis, chronic obstructive pulmonary disease, liver disease, endocrine disorder, any medical history of chronic kidney disease, chronic renal failure, end stage renal disease, patients with or without medication for diabetes mellitus, hypertension were excluded.
2.3. Measured variables
Serum level of uric acid (uricase method as described by Fossati et al.)[11], creatinine (modified Jaffe reaction)[12], TC (enzymatic method as described by Allain et al.)[13], HDL-C (precipitation of LDL-C and VLDL-C with phosphotungstic acid and magnesium chloride and treat as TC), LDL-C (Friedewald formula)[14] and TG (Fossati and Prencipe method associated with Trinder reaction)[15] were also measured.
2.3.1. Defining variables
Hypertension was categorized according to blood pressure readings by Joint National Committee VII definitions: normal (systolic <120 mm Hg and diastolic <80 mm Hg), pre-hypertension (systolic 120 to 139 mm Hg or diastolic 80 to 89 mm Hg), hypertension stage I (systolic 140 to 159 mm Hg or diastolic 90 to 99 mm Hg), and hypertension stage II (systolic ≥160 or diastolic ≥100 mm Hg)[9]. In this study only hypertensive patient were taken. So, patients having stage I hypertension and stage II hypertension were taken.
The formula of Cockcroft and Gault was used[16].
For creatinine clearance (Ccr) in males:
Ccr=[140-age (years)]×weight (kg)×88.4/[72×serum creatinine (µmol/L)]
A companion equation for women was proposed, based on their 15% lower muscle mass (on average):
Ccr = [140-age (years)]×weight (kg)×88.4×0.85/[72×serum creatinine (µmol/L)]
BMI was calculated as weight in kilograms divided by height in meters squared.
2.3.2. Other variables
Age, sex, weight, height, smoking status (never, past, or current), physical activity, alcohol intake and family history of hypertension were collected after having a written consent from participants.
Ethical committee approval: Ethical approval was taken from the ethical board of Institute of Medicine, Kathmandu.
2.4. Data management and statistical analysis
The data was analyzed using Excel 2003, R 2.8.0 Statistical Package for the Social Sciences (SPSS) for Windows Version 16.0 (SPSS Inc; Chicago, IL, USA). Association between hypertension and hyperuricemia was tested by Chi-square test and odds ratio was also calculated. Comparison of mean of continuous data between hypertensive cases and normal healthy control group was tested by student t-test. A P-value of <0.05 (two-tailed) was used to establish statistical significance.
3. Results
Among the patients visiting medical OPD and nephrology unit of Tribhuvan University Teaching Hospital from 2009 February to 2011 August, only 205 patients with newly diagnosed hypertension and 205 normotensive healthy controls were included in this study. In the cases, 116 patients were males and 89 were females. Control comprised of 112 males and 93 females.
The demographic and biochemical characteristics of study participants are depicted in Table 1. The median age of the participants was 44 years. We matched the age and sex between the newly diagnosed hypertension cases and normotensive healthy controls. Table 1 shows that the hypertensive cases were less physically active compared with normotensive healthy controls. Moreover, hypertensive cases had higher BMI. We adjusted the estimated glomerular filtration rate (eGFR) in both cases and controls. Biochemical profile including serum uric acid, TC, LDL-C and TG were found to be higher in hypertensive cases. However, HDL-C was found to be lower in hypertensive cases.
Table 1. Demographic and biochemical characteristics of the study population.
Characteristics | Cases (n=205) | Controls (n=205) | P-value | |
Demographic | Age (years) median (5th-95th percentile) | 44 (24-65) | 44 (24-65) | matched |
BMI (kg/m2) | 23.59±2.96 (23.19-24.00) | 22.03±1.70 (21.79-22.27) | <0.001** | |
Physical activity (METS) | 10.6 | 12.6 | 0.003* | |
Current smokers (%) | 45 (22%) | 30 (14.6%) | 0.055 | |
Past smokers (%) | 18 (8.8%) | 15 (7.3%) | 0.586 | |
SBP (mm Hg) | 143.99±14.28 (142.02-145.96) | 113.51±6.76 (112.58-114.4) | <0.001** | |
DBP (mm Hg) | 96.61±7.24 (95.61-97.61) | 74.44±5.12 (73.73-75.15) | <0.001** | |
Family history of hypertension (%) | 112 (54.6%) | 81 (39.5%) | 0.002* | |
Fasting biochemical profile | Uric acid (µmol/L) | 290.05±87.05 (278.06-302.04) | 245.24±99.38 (231.50-258.50) | <0.001** |
Uric acid in male (µmol/L) | 311.23±88.04 (295.04-327.42) | 266.12±105.64 (246.33-285.90) | 0.001* | |
Uric acid in female (µmol/L) | 262.44±77.94 (246.02-278.85) | 220.11±85.23 (202.55-237.70) | 0.001* | |
Total cholesterol (mmol/L) | 5.15±1.10 (4.99-5.30) | 4.36±0.59 (4.27-4.44) | <0.001** | |
HDL-C (mmol/L) | 1.050±0.320 (1.010-1.098) | 1.080±0.200 (1.057-1.110) | 0.233 | |
LDL-C (mmol/L) | 3.21±1.06 (3.06-3.36) | 3.27±0.63 (3.18-3.36) | 0.505 | |
TG (mg/dl) | 1.93±0.86 (1.81-2.05) | 1.41±0.52 (1.34.1.48) | <0.001** |
METS: metabolic equivalent task scores.
SI conversion factors: To convert cholesterol to milligram per liter, multiply by 38.61; triglycerides to milligram per liter, multiply by 88.49; and uric acid to milligram per liter, multiply by 0.0168.
Continuous variables were analyzed using the independent-student t-test and categorical variables using the χ2 test. 95% CI was shown in the parenthesis. *: P <0.05, **: P<0.001.
Table 2 shows the categorical association between hyperuricemia and hypertension. To define hyperuricemia, we had taken cut off point 416 µmol/L for males and 357 µmol/L for females[17]. Hyperuricemia found in male hypertensive, female hypertensive and total hypertensive were found to be 28.4%, 29.2% and 28.8% respectively. Similarly, hyperuricemia found in male healthy controls, female healthy controls and total normal healthy controls were found to be 14.3%, 12.9% and 13.7% respectively.
Table 2. Distribution of study population according to hyperuricemia in male and female (SUA≥416 µmol/L for male and ≥357 µmol/L for female).
Hyperuricemia (µmol/L) | Male population |
Female population |
Total study population |
|||||
Hypertension | Control | Hypertension | Control | Hypertension | Control | |||
Total number | 116 | 112 | 89 | 93 | 205 | 205 | ||
Hyperuricemia | 33 (28.4%) | 16 (14.3%) | 26 (29.2%) | 12 (12.9%) | 59 (28.8%) | 28 (13.7%) |
Statistical significance at the level of P<0.05. P value obtained from Chi-square test.
Odds ratio (total): 2.555 (95% CI: 1.549-4.213), P<0.001.
Odds ratio (male): 2.386 (95% CI: 1.226-4.61), P<0.01.
Odds ratio (female): 2.786 (95% CI: 1.304-5.951), P<0.01.
Table 3 shows the partial (adjusted) spearman correlation between different biochemical markers, DBP and SBP. Most of the biochemical markers are associated to each other and with DBP and SBP.
Table 3. Partial spearman correlation among biochemical profile markers, age and BMI.
SBP | DBP | BMI | TC | HDL-C | LDL-C | TG | Age | |
Uric acid | 0.221 (0.000)* | 0.201 (0.000)* | 0.154 (0.002)* | 0.115 (0.02) | -0.173 (0.000) | 0.042 (0.392) | 0.152 (0.002)* | -0.057 (0.251) |
SBP | 1 | 0.8 (0.000)* | 0.289 (0.000)* | 0.313 (0.000) | -0.083 (0.093) | -0.058 (0.238)* | 0.307 (0.000)* | 0.074 (0.134) |
DBP | 1 | 0.242 (0.000)* | 0.32 (0.000) | 0.058 (0.241) | -0.089 (0.073)* | 0.346 (0.000)* | 0.034 (0.0.487) | |
BMI | 1 | 0.093 (0.06)* | -0.02 (0.68) | -0.05 (0.309)* | 0.168 (<0.001)** | -0.043 (0.382) | ||
TC | 1 | -0.022 (0.655) | 0.797 (0.000)** | 0.204 (0.000)* | 0.014 (0.782) | |||
HDL-C | 1 | -0.235 (0.000)* | -0.004 (0.937) | -0.033 (0.502) | ||||
LDL-C | 1 | -0.094 (0.056)* | 0.005 (0.919) | |||||
TG | 1 | -0.067 (0.174) | ||||||
Age | 1 |
UA: uric acid.
*: Statistically correlated at the level of P<0.05, **: statistically correlated at the level of P<0.001
4. Discussions
In this cross sectional case control study we observed the strong positive association between hyperuricemia and hypertension. We observed that 28.8% of patients had hyperuricemia with hypertension. Garrick et al. found 31% of their patients had hyperuricemia with hypertension[17]. We observed the mean level of serum uric acid in hypertension and control were (290.05±87.05) µmol/L and (245.24±99.38) µmol/L respectively (P<0.001). Significant high serum uric acid level in hypertensive patients were also observed by Eisen et al. and Grayson et al[18],[19]. Mean age of our study patients was close to those of Eisen et al.[18] and Grayson et al[19]. Gender ratio (male/female) in our study was 1.25:1 which was less than Feig et al.[20], they showed male/female ratio 1.5:1. We found the mean value of systolic blood pressure and diastolic blood pressure in patients were 143.99±14.28 and 96.61±7.24 respectively which was higher than the mean values of SBP and DBP in patients of Feig et al. study; they found the mean level of SBP and DBP 139 mm Hg and 83 mm Hg respectively.
The serum level of uric acid has been associated with the incident of hypertension and may be important of developing hypertension. Several studies have reported regarding serum uric acid level and hypertension from different part of world including Asia[21]–[24]. However, to the best of our knowledge, this type of study has not been reported from Nepal. This is the first study in Nepalese population to find out the association of serum uric acid level with newly diagnosed hypertension. In this study a positive association between the serum uric acid level and newly diagnosed hypertension was found.
The potential confounding factors including renal function, dyslipidemia, and metabolic syndrome were adjusted between the hypertensive patients and normal healthy control. Somewhat decreasing association was found between the serum level of uric acid and hypertension after adjusting the BMI advocating that associated mechanism may be mediated through obesity. BMI levels of a subject reflect the obesity. Qui et al., also found the association between serum uric acid level and hypertension which was attenuated after the adjustment of waist circumference[24]. The report of our study is similar to Borges et al. Although uric acid has the antioxidant properties, it imparts strong oxidant properties in case of obesity[25]. Both the oxdative stress due to serum uric acid level and inflammation in obesity may influence the patient to an increase risk for hypertension.
In the study of Zang W et al., incident of hypertension was significantly associated with the component of metabolic syndrome[24]. We had taken metabolic syndrome as a potential confounding factor and adjusted it in both cases and controls. In this study, hypertension was significantly correlated with the component of metabolic syndrome. Joint exposure of high serum uric acid level with higher BMI and TG has higher risk factor for progression of hypertension than hyperuricemia alone. Obesity associate with hyperinsulinaemia. Hyperinsulinaemia causes the marked reduction of uric acid excretion. Hyperinsulinaemia also causes decreased sodium and potassium excretion. Overall effect of hyperinsulinaemia is to produce hypertension. Thus high chance of getting hypertension occurs in metabolic syndrome[26].
We use the Cock Croft Gault equation for the estimation of renal function i.e. eGFR. Uric acid excretion declines from the renal tubules with the declining renal function. As a result, level of serum uric acid increases. Furthermore, declining renal function is the potential risk factor for secondary hypertension. By considering this mechanism, we adjusted the renal function in our cases and controls. We also tried to exclude the persons who were chronic alcoholic. Chronic alcoholics can influence the uric acid concentration and may be the cause for hyperuricaemia[27]. However, limited information on feeding habit of our study subjects is our limitation which may influence the level of uric acid.
Study conducted by Cheng X et al. postulated the positive association between aldosterone synthase- 344 C/T polymorphism and hypertension in Han[28]. This type of genetic variation may also have role to the association between serum uric acid and hypertension. Thus we could not exclude this fact for their relation which is also limitation of our study.
In conclusion, the mean value of serum uric acid and the number of hyperuricemia persons were significantly higher in newly diagnosed hypertensive cases compared with normotensive healthy controls. Though the serum uric acid level within the normal reference range, it was strongly and significantly associated with the newly diagnosed hypertension in the study population. In clinical practices, measurement of serum uric acid level may help to identify the risk of hypertension. Moreover, further studies can be carried out to lower the serum uric acid level to maintain a low risk of hypertension or to translate high risk of hypertension into a lower risk of hypertension.
Acknowledgments
The project was funded by Department of Biochemistry, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal, Grant No. 30-956/2013 CEA.
Comments
Background
Hypertension is one of the current emerging community health problem, which is very common affecting one in four individuals and it is associated with the cardiovascular disorder, diabetes mellitus, dyslipidemia which is considered as Metabolic syndrome. Since there are various etiological factors associated with hypertension so it is very difficult to predict which one is the most common cause of hypertension. The current study is based on the association of hyperuricemic with hypertension. The study tries to exemplify the reasonable mechanism(s) through which higher uric acid levels inadvertently affects the blood pressure by controlling the confounding factors.
Research frontiers
The current work is an explicit link of uric acid with hypertension.
Related reports
The exclusion and inclusion criteria of the study are well documented. The study elucidates the various reasons causing hypertension by elevated uric acid levels.
Innovations and breakthroughs
The current study is innovative and gives us an idea to explore further and to re-think why and how uric acid affects the endothelial functions causing hypertension.
Applications
The levels of uric acid is individuals would prompt to check the blood pressure and this study proves that hyperuricemia is associated with hypertension. Though earlier study conducted by Kumar et al., 2009 proves uric acid to be beneficial antioxidant in cardiovascular disorders, but this current study shows it as an etiological factor responsible for hypertension.
Peer review
Over all the paper is very informative and gives very scientific information, which makes us to rethink about the relationship of uric acid and hypertension. It can be an eye-opener to further conducted research on uric acid levels with other disorders related to hypertension.
Footnotes
Foundation Project: Supported by Department of Biochemistry, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal (Grant No. 30-956/2013 CEA).
Conflict of interest statement: We declare that we have no conflict of interest.
References
- 1.Colledge NR, Walker BR, Ralston SH, editors. Davidson's principles and practice of medicine. 21st ed. Edinburg: Elsevier Churchill Livingstone; 2010. [Google Scholar]
- 2.Kuroczycka-Saniutycz E, Wasilewska A, Sulik A, Milewski R. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity in adolescents with primary hypertension. Pediatr Nephrol. 2013;28:1113–1119. doi: 10.1007/s00467-013-2449-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Zhou X, Matavelli L, Frohlich ED. Uric acid: its relationship to renal hemodynamics and the renal renin-angiotensin system. Curr Hypertens Rep. 2006;8:120–124. doi: 10.1007/s11906-006-0007-x. [DOI] [PubMed] [Google Scholar]
- 4.Babinska K, Kovacs L, Janko V, Dallos T, Feber J. Association between obesity and the severity of ambulatory hypertension in children and adolescents. J Am Soc Hypertens. 2012;6:356–363. doi: 10.1016/j.jash.2012.08.002. [DOI] [PubMed] [Google Scholar]
- 5.Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69:928–933. doi: 10.1253/circj.69.928. [DOI] [PubMed] [Google Scholar]
- 6.Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26:269–275. doi: 10.1097/HJH.0b013e3282f240bf. [DOI] [PubMed] [Google Scholar]
- 7.Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. Hypertens Res. 2012;35:1039–1047. doi: 10.1038/hr.2012.138. [DOI] [PubMed] [Google Scholar]
- 8.Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16:3553–3562. doi: 10.1681/ASN.2005050572. [DOI] [PubMed] [Google Scholar]
- 9.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 Report. JAMA. 2003;289:2560–2572. doi: 10.1001/jama.289.19.2560. [DOI] [PubMed] [Google Scholar]
- 10.Grossman A, Prokupetz A, Gordon B, Morag-Koren N, Grossman E. Inter-arm blood pressure differences in young, healthy patients. J Clin Hypertens (Greenwich) 2013;15:575–578. doi: 10.1111/jch.12125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Fossati P, Prencipe L, Berti G. Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem. 1980;26:227–231. [PubMed] [Google Scholar]
- 12.Fabiny DL, Ertingshausen G. Automated reaction-rate method for determination of serum creatinine with the Centrifichem. Clin Chem. 1971;17:696–700. [PubMed] [Google Scholar]
- 13.Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470–475. [PubMed] [Google Scholar]
- 14.Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. [PubMed] [Google Scholar]
- 15.Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28:2077–2080. [PubMed] [Google Scholar]
- 16.Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
- 17.Garrick Bauer RGE, Ewan CE, Neale FC. Serum uric acid in normal and hypertensive australian subjects: from a continuing epidemiological survey on hypertension commenced in 1955. Internal Med J. 2008;2:351–356. doi: 10.1111/j.1445-5994.1972.tb03936.x. [DOI] [PubMed] [Google Scholar]
- 18.Eisen A, Benderly M, Goldbourt U, Haim M. Is serum uric acid level an independent predictor of heart failure among patients with coronary artery disease? Clin Cardiol. 2013;36:110–116. doi: 10.1002/clc.22083. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:102–110. doi: 10.1002/acr.20344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension. JAMA. 2008;300:924–932. doi: 10.1001/jama.300.8.924. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Loeffler LF, Navas-Acien A, Brady TM, Miller ER, 3rd, Fadrowski JJ. Uric acid level and elevated blood pressure in U.S. Adolescents: National Health And Nutrition Examination Survey 1999-2006. Hypertension. 2012;59:811–817. doi: 10.1161/HYPERTENSIONAHA.111.183244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Jin M, Yang F, Yang I, Yin Y, Luo JJ, Wang H, Yang XF. Uric acid, hyperuricemia and vascular diseases. Front Biosci. 2012;17:656–669. doi: 10.2741/3950. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Palmer TM, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Davey Smith G, Lawlor DA, et al. et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ. 2013 doi: 10.1136/bmj.f4262. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Qiu L, Cheng XQ, Wu J, Liu JT, Xu T, Ding HT, et al. et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health. 2013;13(1):664. doi: 10.1186/1471-2458-13-664. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Borges RL, Ribeiro AB, Zanella MT, Batista MC. Uric acid as a factor in the metabolic syndrome. Curr Hypertens Rep. 2010;13:113–119. doi: 10.1007/s11906-010-0098-2. [DOI] [PubMed] [Google Scholar]
- 26.Causevic A, Semiz S, Macic Dzankovic A, Cico B, Dujic T, Malenica M, et al. et al. Relevance of uric acid in progression of type 2 diabetes mellitus. Bosn J Basic Med Sci. 2010;10:54–59. doi: 10.17305/bjbms.2010.2736. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Martínez-Martínez MU, Román-Acosta S, Alvarez-Reyes JM, Oros-Ovalle C, Abud-Mendoza C. [Calciphylaxis, renal failure and gout. A patient with hyperuricemia as a risk factor for death] Rev Med Inst Mex Seguro Soc. 2013;51:218–221. [PubMed] [Google Scholar]
- 28.Cheng X, Xu G. A systemic review of the relationship between aldosterone synthase - 344 C/T polymorphism and hypertension in Han. Clin Exp Hypertens. 2010;32:301–307. doi: 10.3109/10641960903443509. [DOI] [PubMed] [Google Scholar]